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Background: Diabetes is a risk factor for pancreatic cancer but its association with survival 
from pancreatic cancer is poorly understood. Our objective was to investigate the association of 
diabetes with survival among pancreatic cancer patients in a population-based study where 
diabetes history was ascertained before pancreatic cancer diagnosis. 
Methods: We evaluated survival by baseline (1993-2001) self-reported diabetes history (n=62) 
among 504 participants that developed exocrine pancreatic cancer within the Prostate, Lung, 
Colorectal, and Ovarian (PLCO) Cancer Screening Trial. Hazard ratios (HR) and 95% 
confidence intervals (CI) for mortality were estimated using Cox proportional hazards model, 
adjusted for age, sex, body mass index, race, smoking, and tumor stage (local, locally advanced 
and metastatic).  
Results: The multivariable adjusted HR for mortality comparing participants with diabetes to 
those without was 1.52 (95%CI 1.14-2.04, p-value < 0.01). After excluding those diagnosed with 
pancreatic cancer within 3 years of study enrollment, HR for mortality among those with 
diabetes was 1.45 (95%CI 1.06-2.00, p-value=0.02).  
Conclusion: Using prospectively collected data, our findings indicate that diabetes is associated 
with worse survival among patients with pancreatic cancer.  
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Introduction 
Pancreatic cancer is currently the 4th leading cause of cancer death but is projected to be the 2nd 
leading cause before 2020 (Pancreatic Cancer Action Network, 2012). In 2013, 45,220 
Americans will be diagnosed with pancreatic cancer and 85% (38,460) of them will die from the 
disease (Siegel et al, 2013). Thus, identifying factors that impact pancreatic cancer survival is of 
utmost priority.  
The association of diabetes before pancreatic cancer diagnosis and survival among pancreatic 
cancer patients is poorly understood, probably, because few studies have investigated this 
association and most have been clinic-based studies that used retrospectively collected data or 
limited their analyses to pancreatic cancer patients who underwent surgical resection (Dandona 
et al, 2011; Hwang et al, 2013; McWilliams et al, 2010; Olson et al, 2010), although diabetes 
has been associated with an increased overall mortality (Seshasai et al, 2011). Another challenge 
is establishing the temporality of association between diabetes and pancreatic cancer in relation 
to survival because of the bidirectional relationship between diabetes and pancreatic cancer. To 
have a better understanding of whether diabetes impacts pancreatic cancer survival, the 
association of diabetes with pancreatic cancer survival should be evaluated in cohort studies 
where diabetes history is prospectively collected before pancreatic cancer diagnosis but these 
studies are lacking.  
We investigated the association of diabetes with survival among pancreatic cancer patients in the 
Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial, where history of 
diabetes was ascertained before pancreatic cancer diagnosis. This knowledge could be useful in 
the clinical management and risk stratification among pancreatic cancer patients. In addition, it 
could provide an insight into possible mechanistic pathways that might impact survival among 
patients with pancreatic cancer. 
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Materials and Methods 
Design overview, study subjects, and endpoints 
The Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial is a randomized, 
two-armed, controlled trial designed to determine the effects of screening on disease-specific 
mortality for cancers of the prostate, lung, colorectal, and ovaries. The PLCO study design and 
characteristics of the participants have been described in details elsewhere (Zhu et al, 2013). 
Briefly, the PLCO enrolled 154,901 men and women aged 55-74 years from 10 centers in the 
United States between November 1993 and July 2001 (Zhu et al, 2013). Study participants filled 
a baseline questionnaire at study entry where they provided demographic, personal, and medical 
information, including history of diabetes. 
Each eligible participant provided written informed consent. Pancreatic cancer diagnosis was 
determined from yearly questionnaire completed by participants or next of kin as well as state 
registries, death certificates and physician reports and confirmed by PLCO staff (Oaks et al, 
2010). At the time of last follow-up in December 2010, 627 primary newly diagnosed exocrine 
pancreas cancer cases had been identified. Pancreatic cancer stage was abstracted at the PLCO 
centers in categories of localized, locally advanced, and metastatic in 2010 from previously 
collected pathology reports and medical records used for cancer confirmation. Since stage is an 
important prognostic factor, we decided a priori to include only those with information on tumor 
stage in our analyses. Tumor stage was classified as (i) local disease amenable to surgical 
resection; (ii) locally advanced disease with extra-pancreatic extension not amenable to surgical 
resection, but without distant metastases; and (iii) distant metastatic disease. American Joint 
Committee on Cancer (AJCC)/International Union for Cancer Control (IUCC) Tumor-Lymph 
nodes-Metastasis (TNM) staging was converted to the above categories. AJCC/IUCC stages I 
and II corresponds to local disease, stage III corresponds to locally advanced disease, and stage 
IV corresponds to metastatic disease. We excluded participants with missing information on 
tumor stage (N=95) and diabetes (N=28). Therefore, our final analytic cohort for this study 
consisted of 504 exocrine pancreas cancer cases (437 were pancreatic ductal adenocarcinomas, 
PDAC). Baseline characteristics were similar for those who had information on tumor stage and 
those who did not. For instance, 14% of those with no information on stage had a positive history 
of diabetes compared to 12% of those with information on stage (p-value=0.30).  
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Information on deaths and causes of death were obtained by linking the study population to the 
National Death Index (Miller et al, 2000). The institutional review boards of the National Cancer 




We compared baseline characteristics of participants who developed pancreatic cancer by 
diabetes history using chi-square test for categorical variables and Wilcoxon Rank test for 
continuous variables. Survival was calculated from the day of pancreatic cancer diagnosis to the 
day of death or December 2010, whichever came first. We used Cox proportional hazards model 
to calculate the hazard ratios (HR) and 95% confidence intervals (CI) of pancreatic cancer 
mortality by diabetes status. We first adjusted the model for age and tumor stage. In 
multivariable adjusted model, we adjusted for age, sex, body mass index (BMI), smoking status, 
race, and tumor stage. We conducted analyses stratified by sex and stage. Sex and stage were 
excluded from multivariable models stratified on these variables. Furthermore, because 
pancreatic cancer induced diabetes could start 2 years before a diagnosis of pancreatic cancer is 
made, we conducted sensitivity analysis excluding participants who developed pancreatic cancer 
within 3 years of enrollment.  
Survival curves were generated using Kaplan-Meier method and adjusted for age, body mass 
index (BMI), sex, race and stage. P-values presented for the survival curves were derived from 
the multivariable-adjusted Cox proportional hazards model. The proportional hazard assumption 
was tested and satisfied through the use of time dependent covariate method. Statistical analyses 
were performed using SAS 9.3 statistical package (SAS Institute, Cary, NC). Statistical 






Median age at baseline examination was 64 years. Baseline characteristics, by diabetes history, 
are listed in Table 1. Of the 504 participants with incident exocrine pancreatic cancer, 62 (12%) 
reported a history of diabetes before pancreatic cancer diagnosis. Participants with diabetes were 
comparable to those without diabetes for most characteristics except BMI. At the end of the 
follow-up period, 91% of the participants (N=460) had died. Median survival was shorter for 
those with diabetes (92 days) than for those without diabetes (139 days, p-value 0.05). Death 
fractions for diabetic/non-diabetic patients were 92% vs 91%. Most of the deaths among people 
with diabetes occurred during the 500 days of follow-up (Figure 1).  
The majority (93%) of participants had pancreatic cancer listed as cause of death on their death 
certificates (95% among those with diabetes and 93% among those without diabetes). Some 
other causes of death listed include ischemic heart disease (4 among those without diabetes and 1 
among those with diabetes), cerebrovascular disease (4 among those without diabetes and 1 
among those with diabetes).  
A history of diabetes was associated with reduced survival (Figure 1). In multi-variable adjusted 
Cox regression model, the HR for mortality comparing those with diabetes to those without 
diabetes was 1.52 (95% CI 1.14-2.04, p-value < 0.01) (Table 2). In analyses stratified by tumor 
stage, diabetes was associated with a 2.3-fold (95%CI 1.16-4.58) and 1.5-fold (95% CI 1.04-
2.24) greater mortality among those with localized and metastatic diseases, respectively but not 
among those with locally advanced disease (HR=1.17, 95% CI 0.62-2.20). In sensitivity analysis 
excluding participants who developed pancreatic cancer within 3 years of enrollment, diabetes 
was associated with increased hazard of mortality (HR=1.45, 95% CI 1.06-2.00, p-value= 0.02). 
The results were identical in analysis limited to participants with PDAC (n=437) (Supplementary 










In this prospective cohort-based study, we observed that participants who reported having 
diabetes prior to being diagnosed with pancreatic cancer had worse survival compared to those 
who did not have diabetes.  
Previous studies have evaluated the associations of diabetes with survival among pancreatic 
cancer patients using retrospectively collected data and among patients who underwent surgical 
resection, with conflicting results (Chu et al, 2010; Dandona et al, 2011; Hwang et al, 2013; 
McWilliams et al, 2010; Olson et al, 2010). In a large study conducted within the United 
Kingdom, there was no survival difference between those with diabetes and those without 
(Hwang et al, 2013). However, the authors reported increased pancreatic cancer mortality among 
those who had long-term diabetes (>5 years). Diabetes was not associated with survival from 
pancreatic cancer in three clinical studies (Dandona et al, 2011; McWilliams et al, 2010; Olson 
et al, 2010). Our study underscores the need for prospective studies to evaluate the associations 
of diabetes with survival among pancreatic cancer patients. In the Cancer Prevention Study II 
(CPS II), a history of diabetes was associated with higher death rates (Calle et al, 1998) but the 
analyses did not take into account tumor stage.  
Experimental studies suggest that diabetes can impact pancreatic cancer survival though its effect 
on glucose metabolism and insulin resistance-related metabolic markers. There is emerging 
evidence that diabetes alters, and reprograms the intracellular metabolic environment to a 
metabolism more favorable to proliferation (Regel et al, 2012; Sah et al, 2013). Kras, p53 and c-
Myc pathways impact pancreatic cancer proliferation and studies have shown that these 
pathways also affect energy metabolism by influencing glucose and glutamine utilization (Regel 
et al, 2012). In addition, hyperinsulinaemia enhances pancreatic cell proliferation and 
invasiveness either directly or indirectly through its effects on insulin-like growth factor (IGF) 
pathway. Metformin, an anti-diabetic drug, has been shown to improve survival among 
pancreatic cancer patients (Sadeghi et al, 2012), possibly via its impact on insulin/IGF-I 
signaling (Rozengurt et al, 2010). Median overall survival was 15.2 months among pancreatic 
cancer patients treated with metformin compared to 11.1 months among the non-metformin 
group (Sadeghi et al, 2012). A better understanding of the biological mechanisms driving the 
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association between diabetes and pancreatic cancer survival could provide insights into the 
development of targeted therapies for some pancreatic cancer patients.  
Another possible explanation for the worse survival may be because diabetics have more 
comorbidities, especially cardiovascular comorbidities, than those without diabetes. These 
comorbidities might put those with diabetes at a survival disadvantage directly or indirectly since 
physicians may be less likely to use aggressive chemotherapy on patients with diabetes because 
of the comorbidities. Hence, diabetes status may be driving aggressiveness of treatment 
decisions. Nevertheless, in our study cohort, pancreatic cancer was reported as the cause of death 
in 95% of participants with diabetes and 93% of participants without diabetes and there appears 
to be no difference in death due to ischemic heart disease and cerebrovascular accident between 
the two groups. Further, we had no information available on history of chronic pancreatitis. The 
worse survival among those with diabetes could also be related to later stage at diagnosis, 
although information on tumor staging in our data does not support this.  
The major strength of our study is its prospective nature. Information on diabetes was collected 
before pancreatic cancer diagnosis. In addition, we adjusted for stage, which is an important 
determinant of pancreatic cancer survival. Our study has the following limitations. A sizeable 
proportion of diabetes may be undiagnosed. Using hemoglobin A1C concentrations as a 
diagnostic test, up to 19% of people with diabetes in the United States are undiagnosed (Cowie et 
al, 2010). Because history of diabetes was based on self-report, prevalence of diabetes in our 
study population would have been under estimated; hence some participants with diabetes would 
have been misclassified as not having diabetes. Any misclassification, though, would have been 
non-differential. Finally, because PLCO is a multicenter study, patients diagnosed with 
pancreatic cancer were treated at different hospitals in different geographical locations; hence, 
treatment programs which were likely to vary among patients could have contributed to 
differences in survival but we had no information on the treatment programs, particularly 
surgery, received by the patients.  
In conclusion, this survival analysis using incident cases ascertained from the PLCO prospective 
cohort, a history of diabetes prior to pancreatic cancer diagnosis was associated with higher 
mortality among pancreatic cancer patients. Studies characterizing the molecular mechanisms 
driving this association are needed as these can provide insights into relevant pathways that 
could be targeted for possible therapeutic interventions. 
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Table 1. Characteristics of participants with exocrine pancreatic cancer (N=504)1 who had available 
information on tumor stage in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening 
Trial by diabetes history 
 
Characteristics No history of diabetes  
N (%) 
Positive history of diabetes2 
N (%) 
P-value 
Age at baseline   0.95 
≤ 59 100 (22.62) 12 (19.35)  
60-64 127 (28.73) 19 (30.65)  
65-69 122 (27.60) 18 (29.03)  
≥ 70 93 (21.04) 13 (20.97)  
Gender   0.51 
Male 237 (53.62) 36 (58.06)  
Female 205 (46.38) 26 (41.94)  
Race   0.69 
White, Non-Hispanic 380 (85.97) 52 (83.87)  
Black, Non-Hispanic 23 (5.20) 4 (6.45)  
Hispanic 6 (1.36) 2 (3.23)  
Other 33 (7.47) 4 (6.45)  
Body Mass Index at baseline   <0.01 
< 25 kg/m2 163 (37.30) 9 (14.75)  
25-29.99 kg/m2 179 (40.96) 35 (57.38)  
30-34.99 kg/m2 78 (17.85) 12 (19.67)  
≥ 35 kg/m2 17 (3.89) 5 (8.20)  
Smoking Status at baseline   0.68 
Never Smoker 178 (40.27) 23 (37.10)  
Current Smoker 83 (18.78) 10 (16.13)  
Former Smoker 181 (40.95) 29 (46.77)  
Pack Years of smoking   0.49 
Never Smoker 178 (40.27) 23 (37.10)  
<10 36 (8.14) 5 (8.06)  
10-20 43 (9.73) 3 (4.84)  
> 20 185 (41.86) 31 (50.00)  
Mortality Status   0.84 
Dead 403 (91.18) 57 (91.94)  
Alive 39 (8.82) 5 (8.06)  
Cancer Stage   0.35 
Localized  78 (17.65) 15 (24.19)  
Locally Advanced 121 (27.38) 13 (20.97)  
Metastatic 243 (54.98) 34 (54.84)  
Median Survival (days) 139 91.5 0.05 
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1504 participants who developed pancreatic cancer after enrollment had information on tumor stage 




Table 2. Associations of diabetes with mortality among participants with exocrine pancreatic 
cancer in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial.  
 No history of diabetes Positive History of diabetes P-value 
 HR (95% CI) HR (95% CI)  
All Exocrine Pancreas Cancer (N=504)   
Model 1a 1.00 (ref) 1.44 (1.09-1.91) 0.01 
Model 1b 1.00 (ref) 1.52 (1.14-2.04) <0.01 
 
Excluding pancreatic cancer cases diagnosed within 3 years of enrollment (N=404) 
Model 1a 1.0 (ref) 1.40 (1.03-1.91) 0.03 
Model 1b 1.0 (ref) 1.45 (1.06-2.00) 0.02 
aAdjusted for age, and stage 
bAdjusted for age, sex, body mass index (BMI), race, smoking and stage. Sex and stage not 











    
Among Males (N= 272)   
Model 1a 1.0 (ref) 1.46 (1.01-2.18) 0.05 
Model 1b 1.0 (ref) 1.69 (1.15-2.50) 0.01 
    
Among Females (N= 231)   
Model 1a 1.0 (ref) 1.42 (0.92-2.20) 0.12 
Model 1b 1.0 (ref) 1.33 (0.82-2.16) 0.25 
    
Localized (N=93)    
Model 1b 1.0 (ref) 2.31 (1.16-4.58) 0.02 
    
Locally advanced 
(N=133) 
   
Model 1b 1.0 (ref) 1.17 (0.62-2.20) 0.65 
    
Metastatic 
(N=277) 
   
Model 1b 1.0 (ref) 1.52 (1.04-2.24) 0.03 
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Figure 1. Kaplan-Meier survival curves: exocrine pancreas cancer 
 
